Pharma BD Deal Intelligence
Zetia approval came earlier than forecast and was framed as a meaningful boost for both partners, with Merck especially needing it to defend its cholesterol…
Schering-Plough's pitch to Merck for a 2-in-1 ezetimibe/simvastatin combination was a 'marketing masterstroke' that boosted ezetimibe sales and prolonged…
The 2000 ezetimibe joint venture became the strategic foundation that ultimately drove Merck's $41.1B acquisition of Schering-Plough, with Vytorin/Zetia…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Merck and Schering-Plough formed a 50/50 joint venture (Merck/Schering-Plough Pharmaceuticals) in May 2000 to co-develop and co-market ezetimibe in the US and combination products with Merck's simvastatin. Resulted in Zetia (2002) and Vytorin (2004). Foundation for the 2009 Merck-Schering-Plough merger.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Schering-Plough Corporation (joint venture, ezetimibe) (this deal) | 2000 | — | 53 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2000 deals · Merck & Co. Inc. deals · Cardiovascular deals